Skip to content

H2020FP7HORIZON

Astrazeneca AB

Country
SESweden
Defence projects
0
Projects, all programmes
150
As coordinator
8
EU contribution (CORDIS)
EUR 17,186,814
Active
2008 to 2026

Projects

150 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
OPTIMAOptimal treatment for patients with solid tumours in Europe through Artificial intelligenceH20202021ParticipantEUR 0
PERSIST-SEQBuilding a reproducible single-cell experimental workflow to capture tumour cell persistenceH20202021ParticipantEUR 0
COLOTANBoosting advanced doctoral training in innovative colon targeting drugsH20202021ParticipantEUR 281,983
AIDDAdvanced machine learning for Innovative Drug DiscoveryH20202021ParticipantEUR 790,492
PharmaLedgerPharmaLedgerH20202020ParticipantEUR 0
CHAIRC-H Activation for Industrial RenewalH20202020ParticipantEUR 281,983
Gravitate-HealthGravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to TreatmentH20202020ParticipantEUR 0
NEASQCNExt ApplicationS of Quantum ComputingH20202020ParticipantEUR 240,500
H2OH2O Health Outcomes ObservatoryH20202020ParticipantEUR 0
TrainCKDisMultidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discoveryH20202020ParticipantEUR 281,983
CO2PERATECooperation towards a sustainable chemical industryH20202020ParticipantEUR 281,983
PREMIERPrioritisation and Risk Evaluation of Medicines in the EnviRonmentH20202020ParticipantEUR 0
IDEA-FASTIdentifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseasesH20202019ParticipantEUR 0
EU-PEARLEU Patient- cEntric clinicAl tRial pLatformH20202019ParticipantEUR 0
MOBILISE-DConnecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsementH20202019ParticipantEUR 0
HighliftStirling heat pump for high temperature industrial useH20202019ParticipantEUR 930,244
NeuroDeRiskNeurotoxicity De-Risking in Preclinical Drug DiscoveryH20202019ParticipantEUR 0
MELLODDYMachinE Learning Ledger Orchestration for Drug DiscoverYH20202019ParticipantEUR 0
STOPFOPSaracatinib Trial tO Prevent FOPH20202019ParticipantEUR 0
INITIATEINnate-ImmunomeTabolIsm as Antiviral TargEtH20202019ParticipantEUR 281,983

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.